MET and neoplasm: The choice of cabozantinib as a warhead stemmed from its excellent activity against hepatocellular endothelial growth factor receptor (HEGFR or c-Met), endothelial growth factor receptor (EGFR) and other tumor-associated proteins KIT, RET, AXL, TIE-2 and FLT-3 [43,44].